B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

January 19, 2022
Open Access

Diffuse Large B-Cell Lymphoma 18 Years After Bilateral Lacrimal Gland IgG4-Related Disease: Case Report and Literature Review.

Journal of Investigative Medicine High Impact Case Reports
Toshihiko MatsuoKazuya Okada
January 19, 2022

Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.

Pakistan Journal of Pharmaceutical Sciences
Xiao ZhouXiangyong Li
January 19, 2022
Open Access

Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.

Scientific Reports
Alexandre BenoitKoren K Mann
January 19, 2022

Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018.

The Journal of Infectious Diseases
Philip R SpradlingChronic Hepatitis Cohort Study (CHeCS) Investigators
January 19, 2022

Fibrin-Associated EBV-Positive Large B-Cell Lymphoma Incidentally Found Within a Multinodular Goiter.

International Journal of Surgical Pathology
Jean-Louis DargentMichel Hérin
January 17, 2022
Case Report
Open Access

[Malignant psoas syndrome secondary to uterine cervical carcinoma].

Medicina
Ignacio M SantarelliMarcelo J Melero
January 17, 2022

Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
James A DavisAshley E Glode
January 17, 2022

Current salvage therapies in Hodgkin lymphoma.

Leukemia & Lymphoma
Karan Chohan, Stephen M Ansell
January 17, 2022

Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.

Leukemia & Lymphoma
Christopher M MelénBjörn Engelbrekt Wahlin
January 17, 2022

MicroRNA regulation of BAG3.

Experimental Biology and Medicine
Madhu V SinghAyotunde O Dokun
January 17, 2022
Review

Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?

British Journal of Haematology
Tarec Christoffer El-GalalyLars C Gormsen
January 17, 2022
Case Report

Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.

Clinical Pathology
Wan Awatif Wan Mohd ZohdiNor Rafeah Tumian
January 17, 2022

Pathology Characteristics of Lymphomas in Rwanda: A Retrospective Study.

The East African Health Research Journal
Fiacre Mugabe ByiringiroBelson Rugwizangoga
January 17, 2022
Case Report

Primary Bone Lymphoma: A Rare Cause of Chronic Back Pain.

Curēus
Guilherme CunhaFilomena Roque
January 17, 2022

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.

Clinical Lymphoma, Myeloma & Leukemia
Paolo F CaimiMehdi Hamadani
January 17, 2022

Antiulcer activity of proanthocyanidins is mediated via suppression of oxidative, inflammatory, and apoptotic machineries.

Journal of Food Biochemistry
Maha S LokmanRami B Kassab
January 17, 2022

Childhood leukemia and non-Hodgkin's lymphoma survivors lack knowledge about their past disease and possible late effects. I-BFM ELTEC study with Chilean and Croatian participation.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
Ana BeckerEdit Bardi

Sign up to follow this feed and discover related papers.

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Castleman Disease

Castleman disease is a rare disorder that involves an overgrowth of cells in the lymph nodes. Unicentric Castleman disease affects one lymph node, usually in the chest or abdomen. Multicentric Castleman disease affects multiple lymph nodes, commonly located in the neck, collarbone, underarm and groin areas. Discover the latest research on Castleman disease here.

Childhood Vascular Tumor: Genetics

Childhood vascular tumors are formed from cells related to blood vessels or lymph vessels. Here is the latest research on the genetics of childhood vascular tumors.

Chronic Myelogenous Leukemia

Chronic myelogenous leukemia (cml) is a clonal hematopoietic stem cell disorder characterized by the translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Here is the latest research on this disease.

Composite Lymphoma

Composite Lymphoma involves different types of lymphoma cells concurrently. Here is the latest research on T-cell leukemia.

FLT3 Inhibitors in Acute Myeloid Leukemia

FMS related tyrosine kinase 3 (FLT3) is a frequently mutated receptor tyrosine kinase in Acute Myeloid Leukemia. Novel Tyrosine kinase inhibitors against FLT3 are currently in clinical trial. Discover the latest research on FLT3 Inhibitors in Acute Myeloid Leukemia here.

© 2022 Meta ULC. All rights reserved
/feed-previews/b-cell-lymphoma/7dc17878-e4f6-4b08-9889-2a511aabf37d